Advanced Biomed Business Summary

Advanced Biomed Inc. (ADVB) is a medical technology company specializing in the development and commercialization of microfluidic biochip platforms for precision oncology and early cancer detection. The company generates revenue through the sale of proprietary biomedical devices and assay products, including its A+Pre, AC-1000, and A+CellScan systems, alongside recurring sales of corresponding microfluidic chips designed for circulating tumor cell (CTC) enrichment and analysis. As of February 2026, the company has transitioned into a leaner operational model following the $7.35 million disposal of its Hong Kong subsidiary, focusing its core business on the Taiwan-based research and clinical validation of its 3D cell culture platforms. ADVB competes directly with small-cap healthcare firms such as P3 Health Partners (PIII), Basel Medical Group (BMGL), and BioNexus Gene Lab (BGLC). Positioned as a high-risk, micro-cap innovator, ADVB recently executed a 1-for-20 reverse stock split to maintain its Nasdaq listing while leveraging a $25 million equity line of credit to fund ongoing clinical feasibility studies. The company is led by Chairman and CEO Dr. Yi Lu, a semiconductor industry veteran who previously founded Cascade Semiconductor and served as a senior executive at Cypress Semiconductor (NASDAQ: CY). Dr. Lu is supported by Co-founder and CTO Dr. Steven I-Fang Cheng, a former associate research fellow at the Taiwan Semiconductor Research Institute (TSRI) with extensive expertise in biomicrofluidics and biosensor design. The executive team also includes CFO Mingze Yin, who brings over a decade of investment banking experience from firms such as Shanghai Sglcell Biotech. The board of directors features independent members Mingyue Cai, Jing Zhang, and Cheang I Kei, providing oversight in corporate governance and financial compliance. A notable institutional backer is Helena Global Investment Opportunities I Ltd., which provides the company's primary structured funding mechanism through a multi-million dollar purchase agreement.